Redefining MS Treatment:
The Next Frontier
Convelo Therapeutics: Unleashing the Central Nervous System’s Natural Healing Potential
ABOUT US
Meet Convelo
Born from innovative research at Case Western Reserve University by Professors Paul Tesar, PhD, and Drew Adams, PhD, Convelo Therapeutics is ushering in a new era of multiple sclerosis care. Our patented remyelination enhancing therapies offer more than hope – they promise tangible repair and renewal for those living with MS. Partnering with leading academic and medical institutions, we’re pioneering a future where MS doesn’t just pause – it retreats.
OUR
Investors
OUR
Technology
Oligodendrocyte Breakthrough
Myelin
Regeneration
High-Efficiency Remyelination Tech
Oligodendrocyte Breakthrough
At Convelo, our revolutionary drug discovery platform uncovers novel therapeutics, targeting the central nervous system’s myelination pathway, propelling advanced treatments towards groundbreaking clinical results.
Myelin Regeneration
Our approach to MS treatment transcends symptom management. We aim for active repair, revitalization, and restoration, offering patients the opportunity for a fuller, more vibrant life.
High-Efficiency Remyelination Tech
Combining speed and precision, our drug discovery process accelerates remyelination, enhancing both research processes and the potential for promising patient outcomes.
OUR
Team
Founded by professors from Case Western Reserve and led by Derrick Rossi, our team at Convelo Therapeutics blends biotech expertise with visionary entrepreneurship. Our unified mission is to develop groundbreaking therapies for neurological disorders, striving to restore functionality and enhance lives.
